Stock fact sheet · data as of
Vyome Holdings, Inc. (HIND): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · Speculative / Distressed
Is HIND undervalued?
HIND closed at 1.91 on 16 Oct 2026, which is 14% above the GLS average fair value of 1.68 from 2 models. 2 of them value the shares below today's price. Our screens read that as "no margin of safety": the stock is not a value candidate at this price, whatever the quality numbers say.
The average is built from just 2 models (DCF, 10 Cap) - the rest returned nothing because an input they need (dividends, free cash flow, book value) is zero or negative - so treat it with more caution than usual.
The nightly engine files HIND under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for HIND
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 1.86 | -2% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | 1.49 | -22% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | 0.3851 | -80% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 3.50 | +83% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Vyome Holdings, Inc. scores only 3 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 2.7/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC -414.9%, ROE -420.2%, ROA -157.9% - with debt at 0.01 times equity and a free-cash-flow yield of 3.9%.
Vyome Holdings, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Product 86%, Royalty 14% (quarter Q2 FY2026).
Institutional ownership scores 1/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 3 / 9 | ROIC | -414.9% |
|---|---|---|---|
| GLS Moat | 2.7 / 10 | ROE | -420.2% |
| Debt / equity | 0.01 | ROA | -157.9% |
| Free-cash-flow yield | 3.9% | Payout ratio | 0% |
| Institutions | 1 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 22: No options
No options are listed on Vyome Holdings, Inc. in our nightly snapshot. The Wheel Score is therefore capped at 39 (it reads 22) and the stock is left out of every options screen; the fair value and health figures above are still useful for a plain stock position.
Volume runs at 15k shares a day on a market cap of $13M, with a beta of 1.54 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 5 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 7 / 25 | -14% margin of safety | |
| Health | 7 / 20 | Piotroski 3/9 | |
| Moat | 4 / 15 | moat 2.7/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 5 / 20 | 15k shares/day, $13M cap, beta 1.54 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 13 Nov 2026, 28 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Vyome Holdings, Inc. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| TCRX TScan Therapeutics, Inc. | 0.2106 | - | - | 31No options | $13M |
| TVRD Tvardi Therapeutics, Inc. | 1.00 | 2.25 | +56% | 40Weak | $13M |
| ALLR Allarity Therapeutics, Inc. | 0.8327 | 1.15 | +28% | 38No options | $13M |
| PTN Palatin Technologies, Inc. | 7.42 | - | - | 32No options | $13M |
| KTTA Pasithea Therapeutics Corp. | 0.4101 | 7.85 | +95% | 37No options | $14M |
| LPCN Lipocine Inc. | 1.68 | 0.6721 | -150% | 15No options | $14M |
| VICP Vicapsys Life Sciences, Inc. | 0.4000 | - | - | 27No options | $13M |
| BCDA BioCardia, Inc. | 0.9385 | 0.2082 | -351% | 13No options | $14M |
| ANEB Anebulo Pharmaceuticals, Inc. | 0.3100 | 0.3396 | +9% | 26No options | $13M |
| CTXR Citius Pharmaceuticals, Inc. | 0.4600 | 0.9200 | +50% | 45Weak | $13M |
| SYBX Synlogic, Inc. | 1.02 | 1.18 | +14% | 28No options | $12M |
| AEON AEON Biopharma, Inc. | 0.2430 | - | - | 27No options | $12M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about HIND
Is HIND undervalued right now?
No: at 1.91 the stock trades 14% above the GLS average fair value of 1.68 (data as of 16 Oct 2026). The margin of safety is negative.
What is the Wheel Score of HIND and what does it mean?
HIND has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for HIND?
1.68 per share as of 16 Oct 2026 - the simple average of the 2 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Vyome Holdings, Inc. report earnings next?
The next earnings report is due on 13 Nov 2026, 28 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does HIND have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on HIND, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.